Phage Technology in Tumor-Targeting Drug Development

Monoclonal antibodies have been used successfully as cancer-targeted therapy and diagnostics, but the efficacy of these therapies is limited in part by molecular size and nonspecific uptake by the reticuloendothelial system. Peptides are much smaller molecules that can specifically target cancer cells, thus reducing the complications of antibody therapy. Although many endogenous and exogenous peptides have been developed as clinical therapeutics, only some of them consist of cancer-targeting peptides. Combinatorial biological libraries, such as phage-displayed peptide libraries, are potential ligand resources for various cancer-related molecular targets. Target-binding peptides can be selected for affinity from a complex mixture of billions of displayed peptides on phage and further enriched through a biopanning process. Various cancer-specific ligands have been isolated by in vivo and in vitro screening methods. Since several peptides derived from phage-displayed peptide library screening have been developed into therapeutics in current clinical trials, which validates the potential of peptide targeting, phage-display should be further utilized to identify cancer-targeted therapeutics.

Fig 1. Identification of targeting ligands to cancer cells by phage display. (Wu H C, et al., 2006)

Our Solutions

At Creative Biolabs, our researchers can help you be more successful by providing tumor-targeting drugs development solutions based on our phage-displayed peptide library technology. Your needs will be carefully met by our expert scientists who can provide you with comprehensive support before, during and after your experiments.

• Tumor-targeting drugs design and sequence analysis
• Tumor-targeting drugs development
• Phage-displayed peptide library screening
• Measurement of hemolytic activity
• Cytotoxicity assay of Tumor-targeting drugs
• Time-killing analysis
• Screening against recombinant tumor-associated proteins
• Tumor-targeting drugs synthetic, medicinal & process chemistry
• Tumor-targeting peptides isolated from phage-displayed peptide libraries
• In vitro ADME of tumor-targeting drugs
• In vitro & in vivo pharmacology of tumor-targeting drugs

Our Phage-displayed Peptide Library Technology

• We are able to provide peptide array design and scalable, reproducible lithographic synthesis of high-quality peptide arrays with standard operating procedures.
• A series of high-complexity libraries (10⁹) for linear and Cys constraints are available. We screen random libraries to identify peptides with high biological activity.
• Various peptide libraries, such as conformational libraries, have been developed to meet any requirement. Compounds in our libraries can be mixed or screened individually, making screening methods diverse and flexible.
• Simultaneously screen thousands of candidate peptide fragments to dramatically speed up your drug development projects

Our Advantages

• We can also build custom phage display libraries and design screening strategies to meet your specific needs.
• Combining our collaborative approach and extensive scientific expertise in phage display, we can approach your project with the following characterization and development of appropriate biologic.
• Maintaining biosecurity is the key and safest way to avoid cross-contamination of our phage display platforms, and we will try to avoid phage infection.

Creative Biolabs can meet the needs of customers by providing tumor-targeting drugs development solutions on time and on budget. We have in-depth knowledge and experience of the tools and processes involved in the phage projects. Our skilled and dedicated scientific researchers ensure that the most suitable methods and techniques are selected for your project. If necessary, please feel free to contact us.

Reference

• Wu H C, Chang D K, Huang C T. Targeted therapy for cancer[J]. J Cancer Mol, 2006, 2(2): 57-66.

Please kindly note that our services can only be used to support research purposes (Not for clinical use).